NR3C2 and hydrops fetalis: In addition, it is one of the most common factors that impede the optimum pharmaceutical approach to HF, leading to underuse of renin‐angiotensin‐aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs), which are the drugs that offer the most help and have changed the outcomes of HF patients.5